Annual EBITDA
-$321.00 K
+$95.03 M+99.66%
December 31, 2023
Summary
- As of February 22, 2025, TRDA annual EBITDA is -$321.00 thousand, with the most recent change of +$95.03 million (+99.66%) on December 31, 2023.
- During the last 3 years, TRDA annual EBITDA has risen by +$26.02 million (+98.78%).
- TRDA annual EBITDA is now at all-time high.
Performance
TRDA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$20.72 M
-$75.05 M-138.14%
September 30, 2024
Summary
- As of February 22, 2025, TRDA quarterly EBITDA is -$20.72 million, with the most recent change of -$75.05 million (-138.14%) on September 30, 2024.
- Over the past year, TRDA quarterly EBITDA has dropped by -$35.57 million (-239.57%).
- TRDA quarterly EBITDA is now -138.14% below its all-time high of $54.33 million, reached on June 30, 2024.
Performance
TRDA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$61.30 M
-$35.57 M-36.72%
September 30, 2024
Summary
- As of February 22, 2025, TRDA TTM EBITDA is $61.30 million, with the most recent change of -$35.57 million (-36.72%) on September 30, 2024.
- Over the past year, TRDA TTM EBITDA has increased by +$92.31 million (+297.65%).
- TRDA TTM EBITDA is now -36.72% below its all-time high of $96.87 million, reached on June 30, 2024.
Performance
TRDA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TRDA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +99.7% | -239.6% | +297.6% |
| 3 y3 years | +98.8% | +17.3% | +164.3% |
| 5 y5 years | +97.3% | +17.3% | +164.3% |
TRDA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +99.7% | -138.1% | +18.5% | -36.7% | +164.3% |
| 5 y | 5-year | at high | +99.7% | -138.1% | +18.5% | -36.7% | +164.3% |
| alltime | all time | at high | +99.7% | -138.1% | +18.5% | -36.7% | +164.3% |
Entrada Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$20.72 M(-138.1%) | $61.30 M(-36.7%) |
| Jun 2024 | - | $54.33 M(+146.4%) | $96.87 M(+259.2%) |
| Mar 2024 | - | $22.05 M(+290.8%) | $26.96 M(-8500.3%) |
| Dec 2023 | -$321.00 K(-99.7%) | $5.64 M(-62.0%) | -$321.00 K(-99.0%) |
| Sep 2023 | - | $14.85 M(-195.4%) | -$31.02 M(-56.5%) |
| Jun 2023 | - | -$15.57 M(+197.2%) | -$71.28 M(-9.6%) |
| Mar 2023 | - | -$5.24 M(-79.1%) | -$78.83 M(-17.3%) |
| Dec 2022 | -$95.35 M | -$25.05 M(-1.4%) | -$95.35 M(+7.9%) |
| Sep 2022 | - | -$25.42 M(+10.0%) | -$88.40 M(+14.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$23.12 M(+6.2%) | -$77.04 M(+21.2%) |
| Mar 2022 | - | -$21.76 M(+20.3%) | -$63.58 M(+27.1%) |
| Dec 2021 | -$50.01 M(+89.9%) | -$18.10 M(+28.7%) | -$50.01 M(+23.6%) |
| Sep 2021 | - | -$14.06 M(+45.6%) | -$40.47 M(+21.6%) |
| Jun 2021 | - | -$9.66 M(+17.9%) | -$33.29 M(+40.9%) |
| Mar 2021 | - | -$8.19 M(-4.2%) | -$23.63 M(+53.1%) |
| Dec 2020 | -$26.34 M(+124.8%) | -$8.55 M(+24.3%) | -$15.44 M(+124.3%) |
| Sep 2020 | - | -$6.88 M | -$6.88 M |
| Dec 2019 | -$11.72 M | - | - |
FAQ
- What is Entrada Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Entrada Therapeutics?
- What is Entrada Therapeutics annual EBITDA year-on-year change?
- What is Entrada Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly EBITDA year-on-year change?
- What is Entrada Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Entrada Therapeutics?
- What is Entrada Therapeutics TTM EBITDA year-on-year change?
What is Entrada Therapeutics annual EBITDA?
The current annual EBITDA of TRDA is -$321.00 K
What is the all time high annual EBITDA for Entrada Therapeutics?
Entrada Therapeutics all-time high annual EBITDA is -$321.00 K
What is Entrada Therapeutics annual EBITDA year-on-year change?
Over the past year, TRDA annual EBITDA has changed by +$95.03 M (+99.66%)
What is Entrada Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TRDA is -$20.72 M
What is the all time high quarterly EBITDA for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly EBITDA is $54.33 M
What is Entrada Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TRDA quarterly EBITDA has changed by -$35.57 M (-239.57%)
What is Entrada Therapeutics TTM EBITDA?
The current TTM EBITDA of TRDA is $61.30 M
What is the all time high TTM EBITDA for Entrada Therapeutics?
Entrada Therapeutics all-time high TTM EBITDA is $96.87 M
What is Entrada Therapeutics TTM EBITDA year-on-year change?
Over the past year, TRDA TTM EBITDA has changed by +$92.31 M (+297.65%)